Effects of immunotherapy on bronchial hyperresponsiveness in patients with allergic rhinitis

The Allergic Rhinitis is a chronic respiratory disease, induced by a half-full inflammation by IgE in the mucosa that covers the nose; It has an important prevalence of between 10%y 25% of the population and a morbidity with deterioration of the quality of life. Asthma and rhinitis are comorbid diseases that suggest the concept of aunique route, since they share the same immunological mechanism and clinicalcharacteristics that is the HRB presence; although in the rhinitis this is less frequent, its presence is considered a risk factor for the future development of bronchial Asthma. The treatment of Allergic Rhinitis contemplates: Allergen avoidance Pharmacotherapy, specific Immunotherapy, being considered the only therapy able to change the course of the disease. OBJETIVES: 1) To evaluate the effects of the immunotherapy on the HRB of patients with Allergic Rhinitis, after a year of treatment. 2) To value the response to the treatment, by means immunological variables 3) Evaluate the response to the treatment, by clinical variables: Registry medication consumption and score of symptoms. 4) Determinate dose security and efficacity for symptoms control. Randomized design double blind placebo control studied 20 adult patients who presented displayed compatible symptoms with allergic rhinitis, confirmed by skin pricktest (Alergo Pharma). The group placebo control was 8 patients (4 male, 4 female) and the group that received treatment with antigens I include 12 patients (9 m, 3 F) of whom 10 receivedtreatment with Dermatophagoides mixes and 2 patients treated with grass pollen (Alergo Pharma) All the patients were valued at the beginning and the year of treatment with subcutaneous Immunotherapy, considering the following variables: Bronchial measurement of HRB by methacolin challenge. (Chemical Sigma Co)continuous method aerosolization considering positive response a PC20=<16mg/ml...